HTG Molecular HTG Molecular Diagnostics Q1 Revenues Drop 36 Percent For the quarter ended March 31, the Tucson, Arizona-based firm's revenues fell to $1.4 million from $2.2 million a year ago. HTG Molecular Preliminary Q1 Revenues Fall 56 Percent For the three months ended March 31, the firm said that preliminary revenues for Q1 are expected to be $1.4 million compared with $3.2 million a year ago. HTG Molecular Diagnostics FY 2020 Revenues Fall 56 Percent For the year ended Dec. 31, 2020, the firm reported revenues of $8.5 million compared to $19.2 million in 2019, beating the Wall Street estimate of $8.3 million. HTG Molecular Preliminary 2020 Revenues Drop 56 Percent The firm reported preliminary revenues of $8.5 million for full-year 2020, which would beat the consensus Wall Street estimate of $8.0 million. HTG Molecular Completes 1-For-15 Reverse Stock Split The company stock will now trade on a split-adjusted basis on the Nasdaq after reducing its number of shares from 200 million to 26.7 million. Nov 11, 2020 HTG to Expand Disease Reach With New Whole-Transcriptome Profiling Product Mid-2021 Premium Nov 10, 2020 HTG Molecular Diagnostics Q3 Revenues Drop 67 Percent Aug 13, 2020 BioSpyder Seeks Noninfringement Judgment in HTG Molecular Patent Dispute Aug 12, 2020 HTG Molecular Q2 Revenues Drop 66 Percent as COVID-19 Forces Global Facility Closures Aug 10, 2020 HTG Molecular Diagnostics, Qiagen Ink CDx Commercialization, Distribution Agreement Jul 31, 2020 New Products Posted to GenomeWeb: Myriad Genetics, HTG Molecular Diagnostics, Twist Bioscience Jun 26, 2020 HTG Molecular Inks $10M Secured Credit Agreement Jun 12, 2020 HTG Molecular Signs Three European Distribution Agreements May 13, 2020 HTG Molecular Diagnostics Q1 Revenues Drop 31 Percent Due to COVID-19 Global Facility Closures Apr 24, 2020 People in the News: Megan Bailey, Maureen Cronin, Ronald Park, Ingo Chakravarty, More Mar 25, 2020 HTG Molecular Diagnostics' FY 2019 Revenues Drop 11 Percent Feb 13, 2020 Following End of Qiagen Deal, HTG Molecular to Focus on CDx Plans and Other Alliances Premium Jan 13, 2020 HTG Molecular Expects 11 Percent Drop in 2019 Revenues Nov 15, 2019 HTG Molecular Diagnostics Files for $20M Stock Offering Nov 12, 2019 HTG Molecular Diagnostics Revenues Grow 15 Percent; Firm Lowers Full-Year Guidance Oct 11, 2019 In Brief This Week: Cardea, HTG Molecular, Novigenix, Stilla Technologies Oct 7, 2019 HTG Molecular Warned by Nasdaq of Listing Non-Compliance Sep 27, 2019 In Brief This Week: 10x Genomics, Yourgene, HTG Molecular, GenScript, More Sep 19, 2019 HTG Molecular Diagnostics Prices $20M in Stock Offerings Aug 6, 2019 HTG Molecular Q2 2019 Revenues Rise 18 Percent Load More Breaking News Alzheimer's Disease Phosphoproteomics Study Uncovers Signaling Abnormalities Genetic Analysis of H. Pylori Indicates Americas Colonized in One Main Migration Event BillionToOne Raises $55M in Series B Financing GeninCode to Launch Cardiovascular Disease Risk Tests in US With Eversana Top Five Articles on GenomeWeb Last Week: Illumina, Liquid Biopsy, Thermo Fisher Scientific, and More Becton Dickinson Sues Beckman Coulter Over Cell Analysis, Sorting IP The Scan Another Resignation According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug. Novavax Finds Its Vaccine Effective Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19. Can't Be Used The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports. PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.